Companies struggle amid stock market gloom.
作者信息
Mitchell Peter
出版信息
Nat Biotechnol. 2002 Oct;20(10):961-2. doi: 10.1038/nbt1002-961.
PMID:12355102
Abstract
摘要
相似文献
1
Companies struggle amid stock market gloom.
Nat Biotechnol. 2002 Oct;20(10):961-2. doi: 10.1038/nbt1002-961.
2
Europe needs a single, deep capital market.
Nat Biotechnol. 2002 Oct;20(10):960-1. doi: 10.1038/nbt1002-960b.
3
Where the money is.
Nat Biotechnol. 2006 Mar;24(3):240-2. doi: 10.1038/nbt0306-240.
4
Crystal gazing: biotech's financial outlook: the biotech analyst's view.
Nat Biotechnol. 2006 Mar;24(3):261-2. doi: 10.1038/nbt0306-261a.
5
Companies jostle for access to public markets.
Nat Biotechnol. 2003 Dec;21(12):1413-4. doi: 10.1038/nbt1203-1413.
6
European markets target foreign biotechs.
Nat Biotechnol. 2003 Jul;21(7):719. doi: 10.1038/nbt0703-719.
7
The rise of European venture capital for biotechnology.
Nat Biotechnol. 2003 Nov;21(11):1287-91. doi: 10.1038/nbt1103-1287.
8
Hedge funds gain edge by doubling biotech investments.
Nat Biotechnol. 2006 Apr;24(4):373-4. doi: 10.1038/nbt0406-373.
9
Public markets show signs of life.
Nat Biotechnol. 2003 Aug;21(8):833-4. doi: 10.1038/nbt0803-833.
10
Evolving symbiosis--venture capital and biotechnology.
Nat Biotechnol. 2003 Sep;21(9):983-4. doi: 10.1038/nbt0903-983.
Zotero 插件